First epidemiological study links popular weight-loss drugs to stomach paralysis, other serious gastrointestinal conditions
They’re being hailed as an effective way to lose weight, but diabetes drugs like Ozempic may come with a heightened risk of severe gastrointestinal problems.
That’s according to new research from the University of British Columbia showing that medications known as GLP-1 agonists—which includes brands like Wegovy, Ozempic, Rybelsus and Saxenda—are associated with an increased risk of serious medical conditions including stomach paralysis, pancreatitis and bowel obstruction.
While previous studies highlighted some of these risks in patients with diabetes, this is the first large, population-level study to examine adverse gastrointestinal ...













